Reply
Jospehine Simonetti, Lisa Bulkow, Brian J. McMahon, Chriss Homan, Mary Snowball, Susan Negus, James Williams, Stephen E. Livingston – 18 February 2016
Beta‐blockers in 2016: Still the safest and most useful drugs for portal hypertension?
Gennaro D'Amico, Giuseppe Malizia, Jaime Bosch – 18 February 2016
Incidence of hepatocellular carcinoma after seroclearance is not reduced
Chee‐Kiat Tan – 18 February 2016
Daclatasvir combined with sofosbuvir or simeprevir in liver transplant recipients with severe recurrent hepatitis C infection
Robert J. Fontana, Robert S. Brown, Ana Moreno‐Zamora, Martin Prieto, Shobha Joshi, Maria‐Carlota Londoño, Kerstin Herzer, Kristina R. Chacko, Rudolf E. Stauber, Viola Knop, Syed‐Mohammed Jafri, Lluís Castells, Peter Ferenci, Carlo Torti, Christine M. Durand, Laura Loiacono, Raffaella Lionetti, Ranjeeta Bahirwani, Ola Weiland, Abdullah Mubarak, Ahmed M. ElSharkawy, Bernhard Stadler, Marzia Montalbano, Christoph Berg, Adriano M. Pellicelli, Stephan Stenmark, Francis Vekeman, Raluca Ionescu‐Ittu, Bruno Emond, K.
The impact of broader regional sharing of livers: 2‐year results of “Share 35”
Erick B. Edwards, Ann M. Harper, Ryutaro Hirose, David C. Mulligan – 17 February 2016 – In June of 2013, the Organ Procurement and Transplantation Network (OPTN) implemented regional sharing for Model for End‐Stage Liver Disease (MELD)/Pediatric End‐Stage Liver Disease (PELD) candidates with scores reaching 35 and above (“Share 35”). The goal of this distribution change was to increase access to lifesaving transplants for the sickest candidates with chronic liver disease and to reduce the waiting‐list mortality for this medically urgent group of patients.
Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension
Sílvia Vilarinho, Sinan Sari, Güldal Yilmaz, Amy L. Stiegler, Titus J. Boggon, Dhanpat Jain, Gulen Akyol, Buket Dalgic, Murat Günel, Richard P. Lifton – 13 February 2016 – Despite advances in the diagnosis and management of idiopathic noncirrhotic portal hypertension, its pathogenesis remains elusive. Insight may be gained from study of early‐onset familial idiopathic noncirrhotic portal hypertension, in which Mendelian mutations may account for disease.
Liver capsule: Mechanisms of alcoholic hepatitis
Bernd Schnabl – 11 February 2016
Liver capsule: Mechanisms of alcoholic hepatitis
Bernd Schnabl – 11 February 2016
Is increased hepatitis C virus case‐finding combined with current or 8‐week to 12‐week direct‐acting antiviral therapy cost‐effective in UK prisons? A prevention benefit analysis
Natasha K. Martin, Peter Vickerman, Iain F. Brew, Joan Williamson, Alec Miners, William L. Irving, Sushma Saksena, Sharon J. Hutchinson, Sema Mandal, Eamonn O'Moore, Matthew Hickman – 10 February 2016 – Prisoners have a high prevalence of hepatitis C virus (HCV), but case‐finding may not have been cost‐effective because treatment often exceeded average prison stay combined with a lack of continuity of care. We assessed the cost‐effectiveness of increased HCV case‐finding and treatment in UK prisons using short‐course therapies.
FoxO3 inactivation promotes human cholangiocarcinoma tumorigenesis and chemoresistance through Keap1‐Nrf2 signaling
Li Guan, Lei Zhang, Zhicheng Gong, Xiaonan Hou, Yuxiu Xu, Xinhua Feng, Hongyang Wang, Han You – 9 February 2016 – FoxO transcription factors have been reported to play pivotal roles in tumorigenesis and drug resistance. The mechanisms underlying the tumor suppression function of FoxOs in human cancers remain largely unknown. Aberrant expression and activation of Nrf2 often correlate with chemoresistance and poor prognosis. Here, we report that FoxO3 directs the basal transcription of Kelch‐like ECH‐associated protein 1 (Keap1), an adaptor protein that bridges Nrf2 to Cul3 for degradation.